Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRN | P28799 | 2/20 | 0.42 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.42 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
| ▸ | PPARA | Q07869 | 1/20 | 0.39 |
| ▸ | NPPA | P01160 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | ACE | P12821 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27171436 | 1.00 | GRN (0.42) | GRNSORT1SCN9APTPN1FFAR1 | |
| SCHEMBL27204735 | 0.91 | LTA4H (0.42) | GRNSORT1SCN9APTPN1FFAR1 | |
| SCHEMBL27171401 | 0.91 | LTA4H (0.42) | GRNSORT1SCN9APTPN1FFAR1 | |
| SCHEMBL29123472 | 0.91 | GRN (0.42) | GRNSORT1SCN9APTPN1FFAR1 | |
| SCHEMBL24665364 | 0.90 | FFAR1 (0.39) | SCN9AFFAR1PPARGCTSL | |
| SCHEMBL30006150 | 0.90 | LTA4H (0.38) | GRNSORT1FFAR1NPSR1PPARG | |
| SCHEMBL24665367 | 0.90 | LTA4H (0.38) | GRNSORT1FFAR1NPSR1PPARG | |
| SCHEMBL29123537 | 0.89 | MAPK1 (0.42) | GRNSORT1SCN9APTPN1FFAR1 | |
| SCHEMBL29123526 | 0.88 | PTPN1 (0.42) | GRNSORT1SCN9APTPN1FFAR1 | |
| SCHEMBL29123439 | 0.86 | LTA4H (0.53) | SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | NOVARTIS PHARMA AG (CH) | 2024-06-20 | — | — | US | disclosed |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | NOVARTIS AG (CH) | 2024-03-19 | — | — | US | disclosed |
| CN-117015537-A | Heteroaryl aminopropanol derivatives as inhibitors of LTA4H | 诺华股份有限公司 | 2023-11-07 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199593-A1 | Novel Heteroaryl Aminopropanol Derivatives | CYP3A43, CYP3A5, CYP51A1 | GRN 1016/4885SORT1 1525/4885SCN9A 2922/4885 |
| US-11932630-B2 | Heteroaryl aminopropanol derivatives | CYP3A43, CYP11B2, ADRB3 | GRN 3180/4885SORT1 1147/4885SCN9A 1338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.